FDA Panel Skeptical of Controversial ALS Drug Ahead of Vote

TUESDAY, Sept. 6, 2022 – A U.S. Food and Drug Administration panel will once again consider approval for an experimental drug for ALS, a rare second review for a disease that has no cure.
The same panel that will meet Wednesday voted last March...